Results 51 to 60 of about 748,511 (316)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Percutaneous Wearable Biosensors: A Brief History and Systems Perspective

Advanced Sensor Research
Wearable biosensors are envisioned to disrupt both delivery and accessibility of healthcare by providing real‐time, continuous monitoring of informative and predictive physiological markers in convenient, user‐friendly, and portable designs.
Kaila L. Peterson, Rajendra P. Shukla, Michael A. Daniele   +2 more
doaj   +1 more source

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection

Pharmaceutics, 2021
Most antiretroviral medications for human immunodeficiency virus treatment and prevention require high levels of patient adherence, such that medications need to be administered daily without missing doses.
Irin Tanaudommongkon, Asama Tanaudommongkon, Xiaowei Dong   +2 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals marked functional differences

, 2010
Depot-dependent differences in adipose tissue physiology may reflect specialized functions and local interactions between adipocytes and surrounding tissues.
Kelder, T.A.J., Kooistra, Teake, MÜLLER M, Manieri, Monia, Evelo, C.T.A., Cinti, Saverio, Kelder, T., Saverio Cinti, Cinti, S., Müller, M.R., BOEKSCHOTEN M, Kelder, Thomas, MANIERI M, Manieri, M., Drevon, C.A., Evelo, C.T.A.; id_orcid, Christian A Drevon, Monia Manieri, Teake Kooistra, Chris Evelo, Boekschoten, M.V., Robert Kleemann, EVELO C, Müller, Michael, Caesar, R., KELDER T, Boekschoten, M., Christian A. Drevon, Thomas Kelder, Michael Müller, Robert Caesar, KOOISTRA T, Caesar, Robert, Kooistra, T., Kleemann, R., Robert Caesar, Michael Müller, Mark Boekschoten, Boekschoten, Mark, KLEEMANN R, Kleemann, Robert, Evelo, C., Evelo, Chris, Müller, M., DREVON CA, Drevon, Christian A., CAESAR R   +46 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Hematological and biochemical effect of subcutaneous administration of robenacoxib in different goat breeds [PDF]

Eurasian Journal of Veterinary Sciences, 2023
Aim: This study aimed to investigate the effect of robenacoxib on hematological and biochemical parameters in healthy Alpine and Saanen goats 24 hours after subcutaneous administration.
Zeynep Ozdemir Kutahya, Petek Piner Benli   +1 more
doaj  

An Unusual Presentation of Hydatid Disease in a Child: A Case Report

The Surgery Journal, 2021
The subcutaneous localization of the hydatid cyst in the abdominal wall is rarely encountered particularly in the pediatric population and is sometimes difficult to diagnose preoperatively.
Kamal El Haissoufi, Abdelouhab Ammor, Imane Kamaoui, Houssain Benhaddou   +3 more
doaj   +1 more source

Evaluation of subcutaneous proleukin (Interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants

, 2006
Background: ESPRIT, is a phase III, open-label, randomized, international clinical trial evaluating the effects of subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART) versus ART alone on HIV-disease progression and death in ...
Tambussi, G., Tambussi, G, Law, MG, Law, M.G, ESPRIT Research Group, Pereira, LC, Pereira, L.C., Lopez, JC, Knysz, B, Lopez, J. C., Arduino, R., Pett, S.L., Reiss, P, Pollack, S., Arduino, R, Pett, S. L., Lopez, J.C., Wand, H, Knysz, B., Pereira, L. C., Wand, H., Emery, Sean, Law, M. G., Pollack, S, Reiss, P., Pett, SL, Mallal, S.   +26 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source